Decoding the Mechanism of Shen Qi Sha Bai Decoction in Treating Acute Myeloid Leukemia Based on Network Pharmacology and Molecular Docking

Jia, Guanfei; Jiang, Xin; Li, Zhiqiang; Ding, Xin; Ling, Lei; Xu, Shuangnian; Gao, Ning

doi:10.3389/fcell.2021.796757

Cited by 11 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the ORR of MDS-EB-1 in this paper was 75.0%, with a median survival time of 11.5 months and ORR of MDS-EB-2. It was 62.5% with a median survival time of 6.5 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) months, suggesting that azacytidine and B-cell lymphoma/leukemia-2 inhibitors may be more effective than MDS-EB-2 in the treatment of MDS-EB-2. This seems to be consistent with the [20].…”

Section: Discussionmentioning

confidence: 99%

“…Based on disease typing analysis, MDS-EB-1 was 4 cases, ORR was 75.0% (3/4), CR was 1 case, mCR was 2 cases, and accompaniment was HI1. In one case, the median survival time was 11.5 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) months for 1 case with disease stabilization, the MDS-EB-2 was 8 cases, the ORR was 62.5% (5/8), and the mCR was 5. In 3 cases, the disease was stable, and the median survival time was 6.5 (3 to 19) months.…”

Section: 2mentioning

confidence: 97%

“…1 case of CR, 3 cases of mCR, 1 case with HI, and 1 case of stable disease were as follows. As of February 1, 2021, the above median survival times were 13 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22), 11 (8.5-22), and 13 (8.5-22) months, respectively. There were 9 cases of MDS comutation, ORR was 55.5% (5/ 9), CR was 1 case, mCR was 4 cases, with HI 1 patient, disease stable 4 patients, median survival time > AML comorbid mutation 5 patients, ORR of 60.0% (3/5), mCR 3 patients with 1 case of HI, and 2 cases of treatment failure, and the median survival time was 13 (3-14) months, see Table 3.…”

Section: Gene Mutations Of Azacytidine and B-cell Lymphoma/mentioning

confidence: 98%

“…In a variety of AML-targeted therapies [ 7 ], direct stimulation of the mitochondrial apoptosis pathway of cancer cells is a new therapeutic strategy. This pathway is regulated by the Bcl-2 gene protein family, which overexpresses tumor cells to evade apoptosis and become resistant to a variety of antineoplastic drugs [ 8 ]. Inhibiting the expression of Bcl-2 family proteins inhibits the formation of tumor neovascularization, thereby inhibiting tumor metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Wang¹,

Huang²,

Liu³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To investigate the efficacy and safety of azacytidine and B-cell lymphoma/leukemia-2 inhibitors in the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods. The clinical data of 31 patients with AML/MDS who were clearly diagnosed with AML/MDS were analyzed from 2018.10 to 2021.02, and the total amount of azacyclonol and B-cell lymphoma/leukemia-2 inhibitor was used for single or combined chemotherapy, with a total amount of 75 mg/m2 ∗ 7 d, divided into 7-10 days of continuous subcutaneous injection, every 28-30 days for a course of treatment. Overall response rate (ORR), median survival, poor response, and genetic mutations were observed. Results. A total of 104 courses of treatment were completed in 31 patients, the median course was 3 (1–12), and 6 patients who did not complete 2 courses of treatment were not counted in the statistics. After 2 courses, ORR was 72.0%, CRES was 2 (8.0%), mCR was 16 (64.0%), disease stable was 5 (20.0%), treatment failures were 2 (8.0%), mortality was 40.0%, and median survival time was >5 months. Single-agent and combined ORR was 64.3% and 81.8%, respectively, with median survival of 7.25 and 9 months; ORR for MDS and AML was 66.7% and 76.9%, respectively, median survival of 8 and 11 months was 66.7% and 80.0% of ORRs at 260 and V60 years, respectively, and median survival of 7 and 11.5 months; MDS-EB-1. The ORR of MDS-EB-2 was 75.0% and 62.5%, respectively, with median survival times of 11.5 and 6.5 months. During 2 courses and 4 courses, the rate of transfusion dependence was 64.0% and 55.5%, respectively. Fifteen cases were detected by second-generation sequencing, and the results were 14 cases of combined gene mutations. Conclusion. Azacytidine and B-cell lymphoma/leukemia-2 inhibitors have good efficacy and high safety in the treatment of AML and MDS, and the combined treatment is better than that of monotherapy, but the side effects of combination therapy are large.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: 2mentioning

confidence: 97%

Section: Gene Mutations Of Azacytidine and B-cell Lymphoma/mentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Wang¹,

Huang²,

Liu³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Molecular docking is utilized to understand the relation between ligands and receptors and the manufacturing and design of new medications [11,12]. Currently, the joint use of network pharmacology and molecular docking has been efficiently applied to the study of TCM and its compound prescriptions [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal Antihypertensive Effect of Gedan Jiangya Decoction

Liu

Mohammed

Lü

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Primary hypertension is understood as a disease with diverse etiology, a complicated pathological mechanism, and progressive changes. Gedan Jiangya Decoction (GJD), with the patent publication number CN114246896A, was designed to treat primary hypertension. It contains six botanical drugs; however, the underlying mechanism is uncertain. We utilized network pharmacology to predict the active components, targets, and signaling pathways of GJD in the treatment of primary hypertension. We also investigated the potential molecular mechanism using molecular docking and animal experiments. The Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP), the Protein Database (UniProt), and a literature review were used to identify the active components and related targets of GJD’s pharmacological effects. The GeneCards, Online Mendelian Inheritance in Man (OMIM), Therapeutic Target Database (TTD), and DrugBank databases were utilized to identify hypertension-related targets. Based on a Venn diagram of designed intersection targets, 214 intersection targets were obtained and 35 key targets for the treatment of hypertension were determined using the STRING data platform and Cytoscape software. The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of key targets revealed that the relevant molecular action pathways of GJD in the treatment of hypertension include the Toll-like receptor, MAPK, PI3K-Akt, and renin-angiotensin signaling pathways. A GJD active ingredient-key target-pathway connection diagram was created using Cytoscape software, and 11 essential active components were selected. Molecular docking was then used to verify the binding activity of key targets and key active ingredients in GJD to treat primary hypertension. The results of this study indicate that AGTR1, AKT1 with puerarin, EDNRA with tanshinone IIA, MAPK14 with daidzein, MAPK8 with ursolic acid, and CHRM2 with cryptotanshinone had high binding activity to the targets with active components, whereas AGTR1 was selected as target genes verified by our experiment. HPLC was utilized to identify the five active ingredients. Experiments in high-salt rats demonstrated that GJD might decrease the expression of AGTR1 in the kidney and thoracic aorta while increasing the expression of eNOS by preventing the activation of the renin-angiotensin pathway, thereby reducing lowering systolic and diastolic blood pressure.

show abstract

Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade

Han,

Wei,

Wang

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Decoding the Mechanism of Shen Qi Sha Bai Decoction in Treating Acute Myeloid Leukemia Based on Network Pharmacology and Molecular Docking

Cited by 11 publications

References 34 publications

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal Antihypertensive Effect of Gedan Jiangya Decoction

Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade

Contact Info

Product

Resources

About